The Therapeutic Goods Administration (TGA) has released a new online form for the clinical trial notification (CTN) scheme. When a clinical trial is investigating the use of a product within Australia, which is not on the Australian Register of Therapeutic Goods (ARTG), or on the ARTG yet being used outside its marketing approval conditions, these […]
Read More
The George Institute was recently profiled in The Lancet; revered as one of the most prestigious, peer reviewed medical journals in the world. The Lancet Vol. 385 April 18, 2015 The feature article in The Lancet spoke of the Institute’s 16 year history from inception to the present time, where the George Institute is known […]
Read More
Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise
Read More
Over the last three years, The George Institute’s Associate Professor Zhang Puhong has led a very important and significant study on Type 2 diabetes in China, the ORBIT (Observational Registry for Basal Insulin Treatment) study. Professor Ji Linong, the chief physician of the department of endocrinology in Peking University People’s hospital, was the principal investigator. […]
Read More
New legislation has taken into effect which simplifies the Hong Kong regulatory process for clinical trial application in that country
Read More
Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.
Read More
Recently, George Clinical’s Project Operations team in Australia volunteered at an OzHarvest program
Read More
George Clinical provides clinical trial management services in Korea through our partner – LSK Global Pharma Services
Read More
